Form 4: Simulations Plus Director Receives Equity Grant

Simulations Plus, Inc. director Sharlene Evans received 1,771 shares of common stock as compensation under the company's 2021 Equity Incentive Plan.

Summary

• Sharlene Evans, an independent director of Simulations Plus, Inc. (SLP), acquired 1,771 shares of common stock.
• The transaction occurred on November 3, 2025.
• The shares were granted as compensation for her role as an independent director.
• The grant was issued under the issuer's 2021 Equity Incentive Plan.
• The acquisition price per share was $0, indicating a grant rather than a purchase.
• Following this transaction, Sharlene Evans beneficially owns a total of 13,280 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (stock grant for director compensation), which is a neutral to slightly positive event as it aligns director interests with shareholders, but does not indicate significant operational or financial changes.

Positives

• Granting stock to independent directors aligns their financial interests with those of shareholders, promoting long-term value creation.
• The compensation is issued under an existing, approved equity incentive plan (2021 Equity Incentive Plan), indicating structured corporate governance.

Negatives

• No direct negatives are apparent from this routine stock grant for director compensation.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

Granting equity as compensation to independent directors is a common practice across various industries, particularly in technology and life sciences, to attract and retain talent while aligning leadership incentives with shareholder value.

Comparison to Industry Standards

• The practice of compensating independent directors with equity, such as stock grants, is a widely accepted corporate governance standard.
• Companies like Bio-Rad Laboratories (BIO), Charles River Laboratories (CRL), and IQVIA Holdings (IQV) in the life sciences and healthcare technology sectors also utilize similar equity-based compensation structures for their non-employee directors to foster long-term alignment and commitment.

Management Changes

Corporate Governance

Legal Proceedings

• No legal or regulatory matters are mentioned in this filing.

Related Party Transactions

• This filing does not disclose any related party dealings beyond the standard director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Recommendation

This Form 4 reports a routine stock grant to an independent director as part of their compensation, which is a standard corporate governance practice. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on their existing fundamental analysis of Simulations Plus, Inc.

Keywords

Simulations Plus, SLP, Sharlene Evans, Director Compensation, Stock Grant, Form 4, Insider Transaction, Equity Incentive Plan, Corporate Governance